Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 13 - Drugs for disorders of the urinary system
Patents for A61P 13 - Drugs for disorders of the urinary system (56,135)
05/2003
05/07/2003EP1307425A1 Novel n-(2-phenyl-3-aminopropyl)naphtamides
05/07/2003EP1307229A1 Combination preparation with an er-beta selective estrogen and a serm or antiestrogen
05/07/2003EP1307220A1 Combined interferon alfa and liposomal-encapsulated all-trans retinoic acid, including preparation and use
05/07/2003EP1307219A2 Methods of inhibiting binding of beta-sheet fibril to rage and consequences thereof
05/07/2003EP1307202A1 Method for the treatment of overactive bladder
05/07/2003EP1307184A2 Drugs for incontinence
05/07/2003EP1223968B1 Use of urodilatin for treating chronic kidney failure with residual kidney functions
05/07/2003EP1200106B1 Composition containing extracts of butyrospermum parkii and the use as medicament or dietary supplement
05/07/2003EP1147110B1 Pyrazino(aza)indole derivatives
05/07/2003EP1019358B1 3,3-diarylpropylamines , their use and preparation
05/07/2003EP1019055B1 Endothelin antagonist and beta receptor blocking agent as combined preparations
05/07/2003EP1007023B1 1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl amine derivatives for lowering the uric level in humans
05/07/2003EP0889880B1 Eprosartan dihydrate and a process for its production and formulation
05/07/2003EP0888330B1 Methods of treating or preventing interstitial cystitis
05/07/2003EP0765314B1 Benzoheterocyclic derivatives useful as vasopressin or oxytocin modulators
05/07/2003CN1416421A New CCRS modulators: benzimidazoles or benzotriazoles
05/07/2003CN1416339A IL-8 receptor antagonsts
05/07/2003CN1415373A Extracting solution of China's herb selaginellae of natural plant
05/07/2003CN1415368A Drug for curing urine retention
05/07/2003CN1415358A Medicament for curing lithiasis.
05/07/2003CN1415353A Formula of Chinese herbal medicine for curing lithiasis
05/07/2003CN1415352A Formula of medicament for curing lithiasis
05/07/2003CN1415346A Oral liquid for nephrosis
05/07/2003CN1415333A Tablet for curing prostatitis
05/06/2003US6559185 Nitromethyl ketone compounds having aldose reduction inhibiting properties and methods for their use
05/06/2003US6559168 Thiazolyl-acid amide derivatives useful as inhibitors of PDE4 isozymes
05/06/2003US6559159 Kappa opioid receptor ligands
05/06/2003US6559153 1-(4-(((4-Amino-6,7-dimethoxy-quinazolin-2-yl)-methyl-amino) methyl)-4-phenyl-piperidin-1-yl)-1-cyclopropyl-methanone; treating disease states ameliorated by blockade of alpha-1 adrenoceptors; sleep/psychological disorders
05/06/2003CA2121674C Biocompatible implant for the timing of ovulation in mares
05/02/2003EP1306376A1 Derivatives of 4-(thio- or selenoxanthene-9-ylidene)-piperidine or acridine and its use as a selective 5-HT2B receptor antagonist
05/02/2003EP1306089A1 Combination of benzimidazoles having angiotensin-II antagonistic activity with diuretics or calcium antagonists
05/02/2003EP1306088A1 Combination of a benzimidazole having angiotensin-II antagonistic activity with a diuretic
05/02/2003EP1306085A1 2-Cyclohexyl-4-phenyl-1H-imidazole derivatives as ligands for the neuropeptide Y5 receptor
05/02/2003EP1305635A2 Methods to identify compounds that modulate rage
05/02/2003EP1305409A2 Renal regulatory elements and methods of use thereof
05/02/2003EP1305404A2 Protein phosphatases
05/02/2003EP1305319A1 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists
05/02/2003EP1305313A1 Fused heterocyclic derivatives as phosphodiesterase inhibitors
05/02/2003EP1305303A1 NOVEL FORM OF (R)- i N /i - 5-METHYL-8-(4-METHYLPIPERAZIN-1-YL)-1,2,3,4-TETRAHYDRO-2-NAPHTHYL]-4-MORPHOLINOBENZAMIDE
05/02/2003EP1305294A2 Imidazolyl derivatives
05/02/2003EP1305293A1 Hexahydro-7-imino-1h-azepin-2-yl-hexanoic acid derivatives as inhibitors of inducible nitric oxide synthase
05/02/2003EP1305274A2 Novel c-4 substituted retinoids
05/02/2003EP1305027A2 Use of an aldehyde 5-oxo-1,2,4-triazine hydrazide for the treatment of cancer
05/02/2003EP1305024A1 Method for treating fibrotic diseases or other indications ic
05/02/2003EP1045846B1 Imidazole derivatives having an inhibitory activity for farnesyl transferase and process for preparation thereof
05/02/2003EP1003557B1 New salts with beneficial organoleptic properties
05/02/2003EP0929578B1 HUMAN ANTIBODIES THAT BIND HUMAN TNFalpha
05/02/2003CA2411015A1 5-(alkylidene-cycloalkyl)- and 5-(alkylidene-heterocyclyl)-pyrazoles
05/02/2003CA2411011A1 5-heteroatom-substituted pyrazoles
05/02/2003CA2410466A1 Hydrazinyl and nitrogen oxide pyrazoles
05/02/2003CA2410364A1 5-heterocyclo-pyrazoles
05/01/2003WO2003035835A2 Glycoprotein compositions
05/01/2003WO2003035684A1 Ee3-protein family and corresponding dna sequences
05/01/2003WO2003035654A1 Phosphonic acid compounds as inhibitors of serine proteases
05/01/2003WO2003035653A1 Pyridothienopyrimidine compound and salt thereof
05/01/2003WO2003035650A1 Entry inhibitor
05/01/2003WO2003035646A2 Derivatives of 4-(thio- or selenoxanthene-9-ylidene)-piperidine or acridine and its use as a selective 5-ht2b receptor antagonist
05/01/2003WO2003035639A1 Pyrimidine compound and medicinal composition thereof
05/01/2003WO2003035638A1 4-imidazolin-2-one compounds
05/01/2003WO2003035635A1 6-hydroxy isoflavones, derivatives and medicaments involving same
05/01/2003WO2003035626A2 Azole derivatives and pharmaceutical compositions containing them
05/01/2003WO2003035620A1 Bicyclic compound
05/01/2003WO2003035102A1 Use of egf to inhibit pathogenic infections of the urogenital tract
05/01/2003WO2003035095A1 Use of histamine to treat liver disease
05/01/2003WO2003035083A1 Drug for treating a fibrotic disease through rna interfence
05/01/2003WO2003035068A1 Macrolides containing pharmaceutical compositions
05/01/2003WO2003035064A1 Pyrazolidinone compounds as ligands of the prostaglandin ep2 and/or ep4 receptors
05/01/2003WO2003035049A2 Use of potent, selective and non-toxic c-kit inhibitors for treating bacterial infections
05/01/2003WO2003035046A2 Salts formed of an at1-receptor antagonist and a cardiovascular agent
05/01/2003WO2003035029A1 Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
05/01/2003WO2003034987A2 Androgen receptor modulators and methods of use thereof
05/01/2003WO2003013656A3 Non-peptide ccr1 receptor antagonists for the treatment of progressive renal fibrosis
05/01/2003WO2003002109A8 Use of tyrosine kinase inhibitors for treating autoimmune diseases
05/01/2003WO2002100351A3 A method for treating inflammatory diseases by administering a ppar-delta agonist
05/01/2003WO2002100336A3 Tissue-specific endothelial membrane proteins
05/01/2003WO2002098897A3 Modified antibodies to prostate-specific membrane antigen and uses thereof
05/01/2003WO2002090352A3 Selective anthranilamide pyridine amides as inhibitors of vegfr-2 and vegfr-3
05/01/2003WO2002074292A3 Hormone replacement therapy
05/01/2003WO2002048148A3 Pyrazolopyridine derivatives
05/01/2003WO2001066572A3 Polynucleotides isolated from e. coli of nature b2/d+ a-, and uses thereof
05/01/2003US20030083505 Benzenedicarboxylic acid derivatives
05/01/2003US20030083466 cDNA clone MY1 that encodes a novel human 7-transmembrane receptor
05/01/2003US20030083374 NAALADase inhibitors useful as pharmaceutical compounds and compositions
05/01/2003US20030083363 Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
05/01/2003US20030083347 Novel tetrahydropyridines, preparation method and pharmaceutical compositions containing same
05/01/2003US20030083333 1,4-Disubstituted benzo-fused compounds
05/01/2003US20030083332 N-heterocyclic derivatives as NOS inhibitors
05/01/2003US20030083320 22-oxa-1a,25-dihydroxyvitamin D3 as an active ingredient; inhibiting mesangial cell proliferation or mesangial matrix production without causing hypercalcemia; treating diabetic nephropathy
05/01/2003US20030083272 Sense mrna therapy
05/01/2003US20030083252 Neuronal uses of BMP-11
05/01/2003US20030083242 Methods and compositions for treating or preventing peripheral neuropathies
05/01/2003US20030083239 Hexapeptide capable of inhibiting beta-chemokine from binding to CCR3 receptor; for treating subject with a disease associated with aberrant leukocyte recruitment and/or activation
05/01/2003US20030082786 PEG-modified uricase
05/01/2003US20030082643 Human monoclonal antibodies to FC alpha receptor (CD89)
05/01/2003US20030082609 Nuceotide sequences coding polypeptide for use in humans therapeutics and diagnostics
05/01/2003US20030082554 Nucleotide sequences coding polypeptide for use in the treatment of immunlological, thyroid, metabolic, bone and pancreatic disorders
05/01/2003CA2464609A1 Use of egf to inhibit pathogenic infections of the urogenital tract
05/01/2003CA2464593A1 6-hydroxy isoflavones, derivatives and medicaments involving same
05/01/2003CA2464344A1 Ee3-protein family and corresponding dna sequences
05/01/2003CA2464111A1 Phosphonic acid compounds as inhibitors of serine proteases
1 ... 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 ... 562